Rheumatology · Clinical trials
ANCA-Associated Vasculitis Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About anca-associated vasculitis — and why its trials are hard
ANCA-associated vasculitis (AAV) is a group of rare, potentially life-threatening small-vessel vasculitides comprising granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA), linked to anti-neutrophil cytoplasmic antibodies against proteinase-3 or myeloperoxidase. Necrotizing inflammation commonly affects the kidneys (rapidly progressive glomerulonephritis), lungs, upper airways, nerves, and skin. Management is divided into remission induction and maintenance. Historically, high-dose glucocorticoids plus cyclophosphamide transformed a near-uniformly fatal disease into a treatable one. The landmark RAVE trial established rituximab as non-inferior to cyclophosphamide for induction, and it is now a cornerstone, especially for relapsing disease. A major advance came in 2021 with avacopan, an oral C5a receptor antagonist, approved as an adjunct on the strength of ADVOCATE; notably, the pivotal NEJM report was later retracted in 2024 over data-integrity issues, though the drug remains FDA-approved. Avacopan's key appeal is substantial glucocorticoid sparing. Ongoing goals are durable remission, relapse prevention, and reducing the heavy toxicity burden of steroids and cytotoxic therapy.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Rituximab (Rituxan) | 2011 | Remission induction (and later maintenance) in GPA and MPA (anti-CD20) | RAVE (phase 3) | Complete remission (BVAS/WG=0, off steroids) at 6 months | 64% rituximab vs 53% cyclophosphamide; met non-inferiority (superior in relapsing subgroup) |
| Avacopan (Tavneos) | 2021 | Adjunctive treatment of severe active GPA and MPA; oral C5a receptor antagonist enabling steroid sparing | ADVOCATE (phase 3; NEJM report retracted 2024, approval retained) | Remission at week 26 (non-inferiority) and sustained remission at week 52 (superiority) | Week 52 sustained remission 65.7% vs 54.9% prednisone taper (superiority met); marked glucocorticoid reduction |
| Cyclophosphamide (Cytoxan) | Established standard (pre-modern approvals; regimen validated by CYCLOPS/NIH studies) | Remission induction in severe organ- or life-threatening AAV | NIH cohorts and CYCLOPS (pulse vs daily oral) | Remission induction | Transformed historically fatal disease to >70-90% remission induction; toxicity drives steroid/cytotoxic-sparing efforts |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in anca-associated vasculitis development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Etanercept (anti-TNF) — WGET (Wegener's Granulomatosis Etanercept Trial) | Did not improve sustained remission when added to standard therapy in GPA | No efficacy benefit and an excess of solid malignancies, discouraging TNF inhibition in AAV |
| Abatacept (CTLA4-Ig) — ABROGATE (phase 3, relapsing non-severe GPA) | Failed to significantly prolong time to relapse versus placebo on standard therapy | Co-stimulation blockade did not add benefit over glucocorticoid-based standard care |
Choosing the right endpoint
Primary endpoints that matter in anca-associated vasculitis trials
- BVAS (Birmingham Vasculitis Activity Score) — Standard measure of disease activity; remission commonly defined as BVAS/WG=0
- Complete/sustained remission — Remission off or on tapered steroids; sustained remission at week 52 was pivotal for avacopan
- Glucocorticoid cumulative dose / sparing — Reducing steroid exposure and toxicity, a central goal driving avacopan's development
- Renal recovery (eGFR/UACR) — Kidney function preservation in glomerulonephritis
How iNGENū runs anca-associated vasculitis trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
ANCA-Associated Vasculitis clinical trials — FAQs
What is the role of rituximab in AAV?
What does avacopan add, and what happened to its trial paper?
Why is reducing glucocorticoids a priority?
Ready to discuss your anca-associated vasculitis trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal